{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:51:23Z","timestamp":1785898283158,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.dld.2018.10.019","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T12:19:13Z","timestamp":1541247553000},"page":"719-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-7428","authenticated-orcid":false,"given":"Vincenzo","family":"Occhipinti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Fanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-8528","authenticated-orcid":false,"given":"Mariagrazia","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2018.10.019_bib0005","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1053\/j.gastro.2003.09.025","article-title":"Prevalence of hepatitis C virus infection in B-cell non-Hodgkin\u2019s lymphoma: systematic review and meta-analysis","volume":"125","author":"Gisbert","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.10.019_bib0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1349-7006.2004.tb03256.x","article-title":"Effect of hepatitis C virus infection on the risk of non-Hodgkin\u2019s lymphoma: a meta-analysis of epidemiological studies","volume":"95","author":"Matsuo","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.dld.2018.10.019_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.20205","article-title":"B-cell non-Hodgkin\u2019s lymphoma and hepatitis C virus infection: a systematic review","volume":"111","author":"Negri","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.dld.2018.10.019_bib0020","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","article-title":"C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies","volume":"15","author":"Dal Maso","year":"2006","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.dld.2018.10.019_bib0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","article-title":"Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium","volume":"6","author":"De Sanjose","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2018.10.019_bib0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/10428190290016845","article-title":"C virus, B-cell proliferation and lymphomas","volume":"43","author":"Gasparotto","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2018.10.019_bib0035","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM199911113412007","article-title":"Cellular origin of human B-cell lymphomas","volume":"341","author":"K\u00fcppers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.10.019_bib0040","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3892\/ijo_00000618","article-title":"Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia?","volume":"36","author":"Libra","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0045","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1053\/j.gastro.2006.09.019","article-title":"Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH","volume":"131","author":"Nieters","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.10.019_bib0050","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2002-10-3230","article-title":"Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study","volume":"102","author":"Mele","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.10.019_bib0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.10.019_bib0060","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.dld.2018.10.019_bib0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","article-title":"Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas","volume":"145","author":"Mazzaro","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.dld.2018.10.019_bib0070","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin\u2019s lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0075","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4254\/wjh.v3.i11.278","article-title":"Hepatitis C virus-related B cell subtypes in non Hodgkin\u2019s lymphoma","volume":"3","author":"Pellicelli","year":"2011","journal-title":"World J Hepatol"},{"key":"10.1016\/j.dld.2018.10.019_bib0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2004-05-1711","article-title":"Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?","volume":"105","author":"Saadoun","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.10.019_bib0085","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis","volume":"23","author":"Peveling-Oberhag","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2018.10.019_bib0090","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0095","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2014-12-618652","article-title":"Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment","volume":"125","author":"Sultanik","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.10.019_bib0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14309\/crj.2015.104","article-title":"Lymphoma remission by interferon-Free HCV eradication without chemotherapy","volume":"3","author":"Lim","year":"2015","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.dld.2018.10.019_bib0105","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/liv.12897","article-title":"HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents","volume":"35","author":"Carrier","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2018.10.019_bib0110","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2014.09.031","article-title":"Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3\/NS4A inhibitor-based treatment. A case report","volume":"62","author":"Rossotti","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.10.019_bib0115","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.10.019_bib0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0125","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","article-title":"Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis","volume":"116","author":"Ennishi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.10.019_bib0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.leukres.2014.11.015","article-title":"Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy","volume":"39","author":"Chen","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.dld.2018.10.019_bib0135","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2447.2447","article-title":"Diffuse B-large cell lymphomas (DBLCL) with hepatitis-C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R-CHOP with antiviral therapy","volume":"106","author":"Musto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.10.019_bib0140","unstructured":"Linee di indirizzo AISF\u2013HCV. http:\/\/www.webaisf.org\/pubblicazioni\/documento-aisf-hcv-2017.aspx. [Accessed 10 March 2017]."},{"key":"10.1016\/j.dld.2018.10.019_bib0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.10.019_bib0150","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0155","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0160","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"Esmo consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2008.06.025","article-title":"Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin\u2019s lymphoma","volume":"49","author":"La Mura","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.10.019_bib0170","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6","article-title":"Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies","volume":"83","author":"Zuckerman","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2018.10.019_bib0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0609.2001.067001045.x","article-title":"Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies","volume":"67","author":"Kawatani","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.dld.2018.10.019_bib0180","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","article-title":"Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy","volume":"17","author":"Visco","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0185","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2005.01.5016","article-title":"Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 groupe d\u2019etude des lymphomes de l\u2019adulte programs","volume":"24","author":"Besson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2018.10.019_bib0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2257.2006.00779.x","article-title":"Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin\u2019s lymphoma patient","volume":"28","author":"Aksoy","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.dld.2018.10.019_bib0195","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood-2006-08-041525","article-title":"Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease","volume":"109","author":"Lake-Bakaar","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.10.019_bib0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.dld.2011.07.016","article-title":"Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy","volume":"44","author":"Coppola","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2018.10.019_bib0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.10.019_bib0210","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1179\/1607845413Y.0000000147","article-title":"Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era","volume":"19","author":"Zaky","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.dld.2018.10.019_bib0215","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/or.2012.1883","article-title":"Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience","volume":"28","author":"Nishikawa","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.dld.2018.10.019_bib0220","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.21564","article-title":"Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin\u2019s lymphomas","volume":"85","author":"Arcaini","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.dld.2018.10.019_bib0225","first-page":"1","article-title":"Curing chronic hepatitis C \u2014 the arc of a medical triumph","author":"Chung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.10.019_bib0230","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00277-017-3129-0","article-title":"Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma","volume":"96","author":"Tsutsumi","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2018.10.019_bib0235","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2018.10.019_bib0240","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.29198","article-title":"Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas","volume":"66","author":"Merli","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.10.019_bib0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.10.019_bib0250","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/gut.2004.048009","article-title":"Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients","volume":"54","author":"Rumi","year":"2005","journal-title":"Gut"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818312155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818312155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:09:37Z","timestamp":1761624577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865818312155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1590865818312155"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2018.10.019","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2018.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}